Pfizer to Cut Costs in Multi-Year Effort
Provided by
Dow Jones
By Josh Beckerman
Pfizer is launching a multi-year cost-reduction program.
The company said first phase is focused on operational efficiencies and is expected to deliver savings of about $1.5 billion by the end of 2027. One-time costs related to the first phase are expected to be about $1.7 billion, and will be recorded primarily in 2024.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
May 22, 2024 13:12 ET (17:12 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Is It Time to Ditch Your Money Market Fund for Longer-Term Bonds?
-
What’s Happening In the Markets This Week
-
4 Reasons Why Today’s Stock Market Is Delivering Impressive Performance
-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Tesla: Shareholder Vote Reduces Key Person Risk
-
After Earnings, Is CrowdStrike Stock a Buy, a Sell, or Fairly Valued?
-
Adobe’s Strong Quarterly Results Drive Share Gains
-
What Does Broadcom’s Stock Split Mean for Investors?
-
5 Ultracheap Stocks to Buy With the Best Returns on Investment
-
Broadcom Earnings: AI Sales Growth Accelerates
-
Oracle Earnings: IaaS Signings More Than Make Up for Miss
-
This Undervalued Stock Is a Buy After Its Dividend Increase